pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

308 catalysts · 4,876 phase readout · 2,342 8k filing · 286 earnings · 274 pdufa · 129 phase 2 completion · 61 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 12 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: earnings×type: patent expiry×type: phase 2 initiation×clear all
type
  • phase readout4,876
  • 8k filing2,342
  • earnings286
  • pdufa274
  • phase 2 completion129
  • phase 1 completion61
phase 1 initiation
32
  • phase 1 2 completion28
  • phase 0 trial completion22
  • phase 2 initiation16
  • therapy area
    • Infectious Disease8
    • Oncology5
    • Immunology3
    • Pulmonology3
    • Cardiology1

    Week of Apr 27, 2026

    50
    ›Apr 28, 2026patent expiry91d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry91d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata
    ›Apr 28, 2026patent expiry91d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry91d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026patent expiry91d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026phase 2 initiation91d agoSRM Medical College Hospital and Research Centre — dexmedetomidine (Phase II Trial Initiation)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Unspecified Central Nervous System Disorders

    full page →dexmedetomidine →source: globaldata
    ›Apr 28, 2026phase 2 initiation91d agoFudan University Shanghai Cancer Center — YZJ-2440 (Phase II Trial Initiation)YZJ-2440

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Solid Tumor

    full page →YZJ-2440 →source: globaldata
    ›Apr 28, 2026phase 2 initiation91d agoShanxi Ruifulai Pharmaceutical Co Ltd — brexpiprazole (Phase II Trial Initiation)BREXPIPRAZOLE

    Therapy area: Central Nervous System. Indication: Schizophrenia

    full page →BREXPIPRAZOLE →source: globaldata
    ›Apr 28, 2026phase 2 initiation91d agoAP Biosciences Inc — B-1962 (Phase II Trial Initiation)B-1962

    Therapy area: Oncology. Indication: Solid Tumor

    full page →B-1962 →source: globaldata
    ›Apr 28, 2026phase 2 initiation91d agoRise Biopharmaceutical Ltd — RP-72 (Phase II Trial Initiation)RP-72

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer

    full page →RP-72 →source: globaldata
    ›Apr 28, 2026phase 2 initiation91d agoInstitute of Medical Sciences of the Banaras Hindu University — ropivacaine (Phase II Trial Initiation)ropivacaine ER

    Therapy area: Central Nervous System, Respiratory. Indication: Pleural Disease, Post-Operative Pain

    full page →ropivacaine ER →source: globaldata
    ›Apr 28, 2026phase 2 initiation91d agoTianjin Lisheng Pharmaceutical Co Ltd — dexamethasone acetate (Phase II Trial Initiation)dexamethasone acetate

    Therapy area: Immunology, Respiratory. Indication: Allergic Rhinitis, Inflammation, Transplant Rejection

    full page →dexamethasone acetate →source: globaldata
    ›Apr 28, 2026earnings91d agoNOVARTIS AG earningsNOVARTIS AG

    Anticipated earnings call for NOVARTIS AG ($NVS).

    full page →yahoo earnings ↗
    ›Apr 28, 2026earnings91d agoINCYTE CORP earningsINCYTE CORP

    Anticipated earnings call for INCYTE CORP ($INCY).

    full page →yahoo earnings ↗
    ›Apr 28, 2026earnings91d agoECOLAB INC. earningsECOLAB INC.

    Anticipated earnings call for ECOLAB INC. ($ECL).

    full page →yahoo earnings ↗
    ›Apr 28, 2026earnings91d agoOrion Group Holdings Inc earningsOrion Group Holdings Inc

    Anticipated earnings call for Orion Group Holdings Inc ($ORN).

    full page →yahoo earnings ↗
    ›Apr 29, 2026phase 2 initiation90d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoGovernment Medical College and Hospital Chandigarh — bupivacaine (Phase II Trial Initiation)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)(daratumumab + hyaluronidase (human recombinant))

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma

    full page →(daratumumab + hyaluronidase (human recombinant)) →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoGoa Medical College — diclofenac (Phase II Trial Initiation)diclofenac ER

    Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor

    full page →diclofenac ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoShenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)RSN-0402

    Therapy area: Respiratory. Indication: Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis

    full page →RSN-0402 →source: globaldata
    ›Apr 29, 2026phase 2 initiation90d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →HH-006 →source: globaldata
    ›Apr 29, 2026earnings90d agoAbbVie Inc. earningsAbbVie Inc.

    Anticipated earnings call for AbbVie Inc. ($ABBV).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoASTRAZENECA PLC earningsASTRAZENECA PLC

    Anticipated earnings call for ASTRAZENECA PLC ($AZN).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoGSK plc earningsGSK plc

    Anticipated earnings call for GSK plc ($GSK).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoREGENERON PHARMACEUTICALS, INC. earningsREGENERON PHARMACEUTICALS, INC.

    Anticipated earnings call for REGENERON PHARMACEUTICALS, INC. ($REGN).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoTEVA PHARMACEUTICAL INDUSTRIES LTD earningsTEVA PHARMACEUTICAL INDUSTRIES LTD

    Anticipated earnings call for TEVA PHARMACEUTICAL INDUSTRIES LTD ($TEVA).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoGLAUKOS Corp earningsGLAUKOS Corp

    Anticipated earnings call for GLAUKOS Corp ($GKOS).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoBIOGEN INC. earningsBIOGEN INC.

    Anticipated earnings call for BIOGEN INC. ($BIIB).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoBausch & Lomb Corp earningsBausch & Lomb Corp

    Anticipated earnings call for Bausch & Lomb Corp ($BLCO).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoSBA COMMUNICATIONS CORP earningsSBA COMMUNICATIONS CORP

    Anticipated earnings call for SBA COMMUNICATIONS CORP ($SBAC).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoAGIOS PHARMACEUTICALS, INC. earningsAGIOS PHARMACEUTICALS, INC.

    Anticipated earnings call for AGIOS PHARMACEUTICALS, INC. ($AGIO).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoIONIS PHARMACEUTICALS INC earningsIONIS PHARMACEUTICALS INC

    Anticipated earnings call for IONIS PHARMACEUTICALS INC ($IONS).

    full page →yahoo earnings ↗
    ›Apr 29, 2026earnings90d agoAvantor, Inc. earningsAvantor, Inc.

    Anticipated earnings call for Avantor, Inc. ($AVTR).

    full page →yahoo earnings ↗
    ›Apr 30, 2026patent expiry89d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

    Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

    full page →isavuconazonium sulfate →source: globaldata
    ›Apr 30, 2026earnings89d agoMERIT MEDICAL SYSTEMS INC earningsMERIT MEDICAL SYSTEMS INC

    Anticipated earnings call for MERIT MEDICAL SYSTEMS INC ($MMSI).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoMerck & Co., Inc. earningsMerck & Co., Inc.

    Anticipated earnings call for Merck & Co., Inc. ($MRK).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoCARDINAL HEALTH INC earningsCARDINAL HEALTH INC

    Anticipated earnings call for CARDINAL HEALTH INC ($CAH).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoDEXCOM INC earningsDEXCOM INC

    Anticipated earnings call for DEXCOM INC ($DXCM).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoELI LILLY & Co earningsELI LILLY & Co

    Anticipated earnings call for ELI LILLY & Co ($LLY).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoSTRYKER CORP earningsSTRYKER CORP

    Anticipated earnings call for STRYKER CORP ($SYK).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoBRISTOL MYERS SQUIBB CO earningsBRISTOL MYERS SQUIBB CO

    Anticipated earnings call for BRISTOL MYERS SQUIBB CO ($BMY).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoAMGEN INC earningsAMGEN INC

    Anticipated earnings call for AMGEN INC ($AMGN).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoBIOMARIN PHARMACEUTICAL INC earningsBIOMARIN PHARMACEUTICAL INC

    Anticipated earnings call for BIOMARIN PHARMACEUTICAL INC ($BMRN).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoBAXTER INTERNATIONAL INC earningsBAXTER INTERNATIONAL INC

    Anticipated earnings call for BAXTER INTERNATIONAL INC ($BAX).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoCORCEPT THERAPEUTICS INC earningsCORCEPT THERAPEUTICS INC

    Anticipated earnings call for CORCEPT THERAPEUTICS INC ($CORT).

    full page →yahoo earnings ↗
    ›Apr 30, 2026earnings89d agoTravere Therapeutics, Inc. earningsTravere Therapeutics, Inc.

    Anticipated earnings call for Travere Therapeutics, Inc. ($TVTX).

    full page →yahoo earnings ↗
    ← prev
    page 1 of 7
    next →
    $GSK51.35+1.20%
    $ORN12.69-1.78%
    $GSK51.35+1.20%
    $NVS155.01-0.72%
    $GSK51.35+1.20%
    $ABBV259.36+0.95%
    $ECL268.75+2.13%
    $AZN169.26+0.59%
    $GSK51.35+1.20%
    $INCY117.67+0.84%
    $REGN656.01+0.63%
    $TEVA30.81-1.19%
    $GKOS153.58+0.95%
    $IONS56.55+1.22%
    $AGIO36.36+0.22%
    $AVTR11.44+0.79%
    $BLCO16.17+1.19%
    $BIIB202.19+0.78%
    $SBAC173.57-0.73%
    $MMSI74.32+1.66%
    $MRK131.07+0.45%
    $CAH228.03+0.91%
    $DXCM71.54+1.50%
    $LLY1196.03+0.86%
    $SYK330.25+3.54%
    $BMY62.09+0.94%
    $BAX22.40+3.37%
    $AMGN376.04+1.22%
    $CORT95.36-1.34%
    $BMRN59.33+0.78%
    $TVTX57.36+1.20%